The importance of sex in pulmonary hypertension

Chest

Volumn 141, Issue 1, 2012, Pages 4-5

  Rich, Stuart ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ESTRADIOL; ESTROGEN; PLACEBO;

DETERIORATION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; EDITORIAL; EXERCISE TEST; HUMAN; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RACE DIFFERENCE; SEX DIFFERENCE;

EID: 84855444574     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2225     Document Type: Editorial

References (11)

1. Gabler NB, French B, Strom BL, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest. 2012;141(1):20-26.
2. Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol. 2010;56(6):696-708.
3. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17β oestradiol in the development of pulmonary arterial hypertension . Cardiovasc Res. 2011;90(2):373-382.
4. Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos. 1999;27(7):810-815. (Pubitemid 29297779)
5. Ma JD, Nafziger AN, Bertino JS Jr. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol. 2004;44(5):447-456. (Pubitemid 38514741)
6. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118(6):429-432. (Pubitemid 23081052)
7. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 2005;26(16):1585-1595. (Pubitemid 41389688)
8. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298(10):1209-1212. (Pubitemid 47403108)
9. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-163.
10. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
11. Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest. 2010;138(5):1234-1239.